Cannabix Technologies to participate in study using marijuana breathalyzer technology
Cannabix is developing marijuana breathalyzer devices to give law enforcement and employers a tool to enhance public safety
October 11, 2022 By Haley Nagasaki
(Globe Newswire) Vancouver — Cannabix Technologies Inc., developer of marijuana breathalyzer devices for law enforcement and the workplace, reports it will be participating in a mid-October study date to test a supplemental version of its FAIMS technology for detection of ∆9-tetrahydrocannabinol (“THC”) and related analytes in human breath in a comprehensive multi-analysis study of subjects under the influence of marijuana in the southern United States.
Cannabix has participated in two testing day events held in two different U.S. cities in June and July. The October event will be held in a new location. In the Southern U.S. study, Cannabix is working alongside toxicologists and law enforcement officers who are testing subjects under the influence of marijuana. The company’s technology (proprietary breath capture and marijuana detection equipment) is being used side by side with several conventional drug screening methods including blood and oral fluid collection. Furthermore, a closed course driving test is planned for the mid-October study date to gauge impairment. Details of the study will be available in due course when disclosure approvals are granted to the company.
Data from previous studies demonstrate very consistent correlation of levels of THC in direct comparison between breath samples collected and analyzed with Cannabix hardware and the current standard of whole blood. The company’s handheld Breath Collection Unit and newly developed laboratory “MS Breath Sampler” are being used together to provide a new ground-breaking method for drug detection that complements gold-standard mass spectrometry (MS) and significantly simplifies laboratory analysis methods, reduces sample turnaround times (thus minimizing operating costs), while maintaining sensitive, precise results.
The company has developed a unique breath capture system, capable of collecting low volatility analytes, such as THC, from a sample size of only approximately five breaths. In addition, the Cannabix device captures analytes efficiently such that the sample preparation steps needed in traditional methods are completely eliminated. The system has detected and confirmed THC in breath out to four hours after smoking with breath samples being stored and analyzed up to two days after sample collection.
Cannabix has been actively participating in breath-blood studies over the course of the year — completing experiments in Ontario (see press release from May 9th, 2022) and alongside law enforcement in the Southern U.S. in June and July (see press releases from July 12th and August 25th, 2022). The study results show that breath levels of THC over time are consistent between subjects, and data demonstrate consistent correlation of levels of THC between breath and whole blood in early time points after smoking.
Print this page